Cyclacel Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 24.48
| CYCC Stock | USD 0.41 0.06 17.14% |
Cyclacel |
Cyclacel Pharmaceuticals Target Price Odds to finish over 24.48
The tendency of Cyclacel Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 24.48 or more in 90 days |
| 0.41 | 90 days | 24.48 | close to zero percent |
Based on a normal probability distribution, the odds of Cyclacel Pharmaceuticals to move over $ 24.48 or more in 90 days from now is close to zero percent (This Cyclacel Pharmaceuticals probability density function shows the probability of Cyclacel Stock to fall within a particular range of prices over 90 days) . Probability of Cyclacel Pharmaceuticals price to stay between its current price of $ 0.41 and $ 24.48 at the end of the 90-day period is about 91.07 .
Given the investment horizon of 90 days Cyclacel Pharmaceuticals has a beta of 0.58 suggesting as returns on the market go up, Cyclacel Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cyclacel Pharmaceuticals will be expected to be much smaller as well. Additionally Cyclacel Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Cyclacel Pharmaceuticals Price Density |
| Price |
Predictive Modules for Cyclacel Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cyclacel Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cyclacel Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cyclacel Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cyclacel Pharmaceuticals is not an exception. The market had few large corrections towards the Cyclacel Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cyclacel Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cyclacel Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.27 | |
β | Beta against Dow Jones | 0.58 | |
σ | Overall volatility | 0.29 | |
Ir | Information ratio | -0.17 |
Cyclacel Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cyclacel Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cyclacel Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cyclacel Pharmaceuticals has high historical volatility and very poor performance | |
| Cyclacel Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K). | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclacel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Cyclacel Pharmaceuticals, Inc. Short Interest Up 906.1 percent in November |
Cyclacel Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cyclacel Stock often depends not only on the future outlook of the current and potential Cyclacel Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cyclacel Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 850.8 K | |
| Cash And Short Term Investments | 3.4 M |
Cyclacel Pharmaceuticals Technical Analysis
Cyclacel Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Cyclacel Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cyclacel Pharmaceuticals. In general, you should focus on analyzing Cyclacel Stock price patterns and their correlations with different microeconomic environments and drivers.
Cyclacel Pharmaceuticals Predictive Forecast Models
Cyclacel Pharmaceuticals' time-series forecasting models is one of many Cyclacel Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cyclacel Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cyclacel Pharmaceuticals
Checking the ongoing alerts about Cyclacel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cyclacel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cyclacel Pharmaceuticals has high historical volatility and very poor performance | |
| Cyclacel Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K). | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclacel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Cyclacel Pharmaceuticals, Inc. Short Interest Up 906.1 percent in November |
Check out Cyclacel Pharmaceuticals Backtesting, Cyclacel Pharmaceuticals Valuation, Cyclacel Pharmaceuticals Correlation, Cyclacel Pharmaceuticals Hype Analysis, Cyclacel Pharmaceuticals Volatility, Cyclacel Pharmaceuticals History as well as Cyclacel Pharmaceuticals Performance. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.